These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 35491523)

  • 1. Non-inferiority and clinical superiority of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors: Systematic analysis of cardiorenal outcome trials in type 2 diabetes.
    Zaccardi F; Kloecker DE; Khunti K; Davies MJ
    Diabetes Obes Metab; 2022 Aug; 24(8):1598-1606. PubMed ID: 35491523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative efficacy of sodium-glucose co-transporter-2 inhibitors, glucagon-like peptide-1 receptor agonists and non-steroidal mineralocorticoid receptor antagonists in chronic kidney disease and type 2 diabetes: A systematic review and network meta-analysis.
    Nguyen BN; Nguyen L; Mital S; Bugden S; Nguyen HV
    Diabetes Obes Metab; 2023 Jun; 25(6):1614-1623. PubMed ID: 36751968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Translating trial results into interpretable risk estimates: Systematic analysis of cardiorenal outcome trials of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors.
    Rizzi A; Kloecker DE; Pitocco D; Khunti K; Davies MJ; Zaccardi F
    Nutr Metab Cardiovasc Dis; 2024 May; 34(5):1129-1133. PubMed ID: 38336546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative safety and cardiovascular effectiveness of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in nursing homes.
    Riester MR; Zullo AR; Joshi R; Daiello LA; Hayes KN; Ko D; Kim DH; Munshi M; Berry SD
    Diabetes Obes Metab; 2024 Aug; 26(8):3403-3417. PubMed ID: 38779879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular protection significantly depends on HbA1c improvement with GLP-1RAs but not with SGLT2 is in type 2 diabetes: A narrative review.
    Scheen AJ
    Diabetes Metab; 2024 Mar; 50(2):101508. PubMed ID: 38158077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on time to outcome in type 2 diabetes cardiorenal outcome trials.
    Rizzi A; Kloecker DE; Pitocco D; Khunti K; Davies MJ; Zaccardi F
    Diabetes Metab Syndr; 2024 Feb; 18(2):102945. PubMed ID: 38262118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists according to the 2019 ESC guidelines and the 2019 ADA/EASD consensus report in a national population of patients with type 2 diabetes.
    Lim CE; Pasternak B; Eliasson B; Danaei G; Ueda P
    Eur J Prev Cardiol; 2023 Jun; 30(8):634-643. PubMed ID: 36582120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do SGLT2 inhibitors and GLP-1 receptor agonists modulate differently the risk of stroke ? Discordance between randomised controlled trials and observational studies.
    Scheen AJ
    Diabetes Metab; 2023 Sep; 49(5):101474. PubMed ID: 37678760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risks of carpal tunnel syndrome and carpal tunnel release surgery in users of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists: A target trial emulation study.
    Su YC; Hsieh PC; Lai EC; Lin YC; Lin YC
    Diabetes Metab; 2024 Jul; 50(4):101545. PubMed ID: 38777141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of novel glucose-lowering therapies on physical function in people with type 2 diabetes: A systematic review and meta-analysis of randomised placebo-controlled trials.
    Ahmad E; Arsenyadis F; Almaqhawi A; Barker M; Jobanputra R; Sargeant JA; Webb DR; Yates T; Davies MJ
    Diabet Med; 2023 Jun; 40(6):e15083. PubMed ID: 36905324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and safety of the combination of sodium-glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies.
    Ahmad A; Sabbour H
    Cardiovasc Diabetol; 2024 Mar; 23(1):99. PubMed ID: 38500154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absolute treatment effects of novel antidiabetic drugs on a composite renal outcome: meta-analysis of digitalized individual patient data.
    Brockmeyer M; Parco C; Vargas KG; Westenfeld R; Jung C; Kelm M; Roden M; Akbulut C; Schlesinger S; Wolff G; Kuss O
    J Nephrol; 2024 Mar; 37(2):309-321. PubMed ID: 38236473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Consistent glycaemic efficacy and safety of concomitant use of iGlarLixi and sodium-glucose co-transporter-2 inhibitor therapy for type 2 diabetes: A patient-level pooled analysis of three randomised clinical trials.
    Giorgino F; Guja C; Aydın H; Lauand F; Melas-Melt L; Rosenstock J
    Diabetes Res Clin Pract; 2024 Mar; 209():111604. PubMed ID: 38447911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists.
    Lin TY; Kang EY; Shao SC; Lai EC; Garg SJ; Chen KJ; Kang JH; Wu WC; Lai CC; Hwang YS
    Diabetes Metab J; 2023 May; 47(3):394-404. PubMed ID: 36872060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of rotator cuff tear and rotator cuff repair surgery comparison between sodium-glucose cotransporter 2 inhibitors and glucagon like peptide-1 receptor agonists: A real-world study.
    Su YC; Hsieh PC; Lai EC; Lin YC
    Diabetes Metab; 2024 Mar; 50(2):101522. PubMed ID: 38341131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medicare formulary restrictions for glucagon-like peptide 1 receptor agonists and sodium glucose cotransporter 2 inhibitors used in type 2 diabetes mellitus: 2019-2023.
    Wisniewski B; Smith E; Kaur J; Sherling C; Vanapalli S; Lussier M
    J Manag Care Spec Pharm; 2024 Jan; 30(1):34-42. PubMed ID: 38153863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of cost-effectiveness in the use of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists.
    Liu M; Hao G
    Eur J Prev Cardiol; 2023 Jun; 30(8):656-657. PubMed ID: 36740456
    [No Abstract]   [Full Text] [Related]  

  • 18. Novel Drugs for Diabetes Also Have Dramatic Benefits on Hard Outcomes of Heart and Kidney Disease.
    Chan JCH; Chan MCY
    Curr Cardiol Rev; 2022; 18(6):e110522204572. PubMed ID: 35546744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of baseline kidney function on the effects of sodium-glucose co-transporter-2 inhibitors on kidney and heart failure outcomes: A systematic review and meta-analysis of randomized controlled trials.
    Maddaloni E; Cavallari I; La Porta Y; Appetecchia A; D'Onofrio L; Grigioni F; Buzzetti R; Holman RR
    Diabetes Obes Metab; 2023 May; 25(5):1341-1350. PubMed ID: 36700422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice.
    Lim LL; Chow E; Chan JCN
    Nat Rev Endocrinol; 2023 Mar; 19(3):151-163. PubMed ID: 36446898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.